Form 4 for GYRE GYRE THERAPEUTICS, INC.
Accepted 2025-05-14 00:00:00 ET · period of report 2025-04-01 · accession 0001140361-25-019053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-14 | 2025-04-01 | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +50.0K | 700.0K | +8% | +$37.5K |
| D | 2025-05-14 | 2025-04-01 | GYRE | Ye Weiguo | COO | M - OptEx | $0.00 | -50.0K | 965.1K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-01 | M | A | 50,000 | $0.75 | 700,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-04-01 | M | D | 50,000 | $0.00 | 965,115 | D | $0.75 · — to 2030-10-31 | 50,000 Common Stock | (F1) These options are vested in full. |